Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Robbins HARP stock SEC Form 4 insiders trading
Andrew has made over 8 trades of the Harpoon Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 19,688 units of HARP stock worth $453,021 on 1 April 2019.
The largest trade he's ever made was exercising 410,582 units of Harpoon Therapeutics stock on 16 December 2017 worth over $1,974,899. On average, Andrew trades about 37,180 units every 71 days since 2014. As of 1 April 2019 he still owns at least 79,682 units of Harpoon Therapeutics stock.
You can see the complete history of Mr. Robbins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Robbins biography
Andrew R. Robbins serves as Independent Director of the Company. Mr. Robbins served as Chief Operating Officer at Array BioPharma Inc., a pharmaceutical company, from March 2015 through its acquisition by Pfizer Inc., a pharmaceutical company, in July 2019, after serving as its Senior Vice President, Commercial Operations from July 2012 to March 2015. From January 2007 to July 2012, Mr. Robbins held management positions at Hospira, Inc., a pharmaceutical and medical device company, including General Manager and Vice President of the U.S. Alternate Site business unit and Vice President of Corporate Development. Prior to Hospira, Mr. Robbins held commercial and leadership positions within Pfizer’s oncology unit. Mr. Robbins holds a B.A. from Swarthmore College and an M.B.A. from the Kellogg School of Management at Northwestern University. Our Board believes that Mr. Robbins’ expertise and experience in the life sciences industry provide him with the qualifications and skills to serve on our Board.
How old is Andrew Robbins?
Andrew Robbins is 44, he's been the Independent Director of Harpoon Therapeutics since 2020. There are 13 older and 1 younger executives at Harpoon Therapeutics. The oldest executive at Harpoon Therapeutics, Inc. is Gerald McMahon, 65, who is the President, Chief Executive Officer, Director.
What's Andrew Robbins's mailing address?
Andrew's mailing address filed with the SEC is C/O HARPOON THERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Harpoon Therapeutics
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt, and Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
What does Harpoon Therapeutics do?
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
What does Harpoon Therapeutics's logo look like?
Harpoon Therapeutics executives and stock owners
Harpoon Therapeutics executives and other stock owners filed with the SEC include:
-
Gerald McMahon,
President, Chief Executive Officer, Director -
Dr. Natalie R. Sacks M.D.,
Chief Medical Offer -
Holger Wesche,
Chief Scientific Officer -
Georgia L. Erbez,
Chief Financial Officer -
Georgia Erbez,
Chief Financial Officer -
Natalie Sacks,
Chief Medical Officer -
Mark Chin,
Independent Director -
Julia Eastland,
Independent Director -
Ronald Hunt,
Chairman of the Board -
Scott Myers,
Independent Director -
Jonathan Drachman,
Independent Director -
Joanne Viney,
Independent Director -
Andrew Robbins,
Independent Director -
Joseph Bailes,
Independent Director -
Karin Thacker,
Vice President - Regulatory Affairs and Quality Assurance -
Omer Siddiqui,
Vice President - Development Operations and Project Management -
Rachael Lester,
Vice President of Corporate Development -
Che-Leung Law,
Vice President - Translational Medicine -
Christopher Whitmore,
Vice President - Finance -
Susan Jones,
Senior Vice President, Product Development -
Dr. Holger Wesche Ph.D.,
Chief Scientific Officer -
Julie M. Eastland,
Pres, CEO & Director -
James B Bucher,
Chief Legal Officer -
Alan Colowick,
Director -
Bio Ventures 2014, L.P.Mpm ...,
-
Ansbert Oncology Impact Fun...,
-
Bio Ventures 2014, L.P.Mpm ...,
-
Patrick Baeuerle,
Director -
Bioscience Plc Arix Bioscie...,
-
Luke Evnin,
Director -
Oncology Impact Fund L.P.On...,
-
Leaf Ventures Iii, L.P.New ...,
-
Leaf Biopharma Opportunitie...,
-
Lauren P Silvernail,
-
Frank J Lanza,
Principal Fin. & Acctng Ofc. -
Luke Nathaniel Walker,
Chief Medical Officer -
& Co., Inc.Merck Sharp & Do...,